DNA Sequencing Market Analysis and Forecast Report 2024

The global DNA Sequencing market size is projected to achieve a lucrative growth based on the advent of technological innovations and extensive clinical applications. The market is expected to be led by consumable products, in terms of both size and growth during the forecast period (2018-2023). This is attributed to the extensive use of consumables for sample preparation, cluster generation, and other processes during the course of experiments.

DNA sequencing make use of various technological platforms for fragmentation and sequencing studies. These technological platforms include sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single-molecule-real-time sequencing, chain termination sequencing, and nanopore sequencing. Sequencing by synthesis is the most widely used platform in sequencing protocols and is the largest contributor to the DNA sequencing market, on the basis of product type. The category is also anticipated to witness fastest growth in demand, during the forecast period.

The key trends observed in the DNA sequencing industry are surge in clinical assessment through personalized genomics, increase in oncological research, demand for easy and fast clinical diagnosis, and adoption of high throughput technology.

The growing collaborations and partnerships among key players is expected to increase their market share in the coming years. For instance, in April 2017, Genome Diagnostics B.V. (GenDx) signed a global reseller agreement with Thermo Fisher Scientific, Inc. next-generation sequencing instruments. Under the agreement, GenDx and its distributors will have the rights to offer an end to end workflow to Human Leukocyte Antigen (HLA) typing laboratories that includes the Ion Torrent brand of next-generation sequencing (NGS) systems and consumables with GenDx assays and analysis software for allelic level HLA typing analyses.

Some of the other key players in the global market include Illumina, Inc, Pacific Biosciences of California, Inc., Siemens AG, ZS Genetics, Inc, Abbott Laboratories, Li-Cor, Inc., F. Hoffmann-La Roche Ltd., Oxford Nanopore Technologies, and Agilent Technologies, Inc.